AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04133714 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: single-channel tDCS
Description: single-channel transcranial direct current stimulation
Study NCT04133714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-channel tDCS
Description: single-channel transcranial direct current stimulation
Study NCT01020903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: 40 mg po pre-op
Study NCT01020903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally, pre-op
Study NCT01751776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 655064
Description: Placebo matching BI 655064 injected subcutaneous.
Study NCT01751776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: BI 655064 injected subcutaneous
Study NCT01477008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPhasic Cartilage Repair Implant
Description: 1 or 2 BiCRI devices, depending on lesion size
Study NCT01477008 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Marrow Stimulation
Description: Microfracture or Subchondral Drilling
Study NCT01086540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: diphenhydramine
Description: Diphenhydramine 50 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed.
Study NCT01086540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine
Description: Diphenhydramine 50 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed.
Study NCT01086540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetaminophen
Description: Acetaminophen 650 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed.
Study NCT01086540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Acetaminophen 650 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed.
Study NCT00861991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perspective taking instruction
Description: Students were asked to take the perspective of their standardized patients during clinical skills examinations
Study NCT03114215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MD1003
Description: capsules 100mg 3 times per day
Study NCT03114215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MD1003
Description: capsules 100mg 3 times per day
Study NCT02348112 — intervention group
Intervention type: DEVICE
Intervention: Transobturator or Retropubic Sling
Description: Both transobturator and retropubic slings are a hammock-like mesh placed underneath the urethra to provide support. A single incision is made in the vaginal wall and two incisions in the abdomen. Tensioning of the sling is achieved by pulling the sling through the abdominal incisions.
Study NCT00330317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: 2.5mg letrozole once-daily
Study NCT00914355 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation
Description: Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver.You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment.Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
Study NCT03851042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Head set in PACU
Description: Use of VR headset to determine post op satisfaction in PACU, decreased pain reduction and opioid consumption
Study NCT03851042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Routine post laparoscopic hysterectomy management (no VR headset)
Study NCT03164928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 1mg/kg BW (up to a maximum of 60 mg) SC Q6M
Study NCT03164928 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: SC Q6M placebo
Study NCT03043625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visceral manipulation
Description: Participants will be instructed to lie down comfortably on a stretcher in the supine position, with lower limbs flexed and abdomen exposed, and the physiotherapist positioned to the right side of the patient. The therapeutic intervention will be began with the left hand of the physiotherapist in contact with the lower region of the stomach, to which a force will be applied so that the organ was moved in an upper and lateral left direction while the right hand controlled and directed the knees of the patient to the right side until the moment when the physiotherapist notice an increase in tension in the stomach region. For the liver manipulation, the same procedures will be followed, however, with contact in the right epigastric region and the knees directed to the left side. The same position will be maintained for each organ treated until the physiotherapist could feel, through touch, a decrease in the tension of the viscera. The mean treatment time will 5 minutes.
Study NCT03043625 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group (CG)
Description: The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
Study NCT03784404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal aspiration
Description: under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material
Study NCT03784404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal aspiration and surgicel injection
Description: under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity
Study NCT03784404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intracytoplasmic sperm injection
Description: Candidates for the standard long protocol received triptorelin 0.1 mg Subcutanous daily starting from day 21 of the previous cycle. On the second day of the stimulation cycle, pituitary downregulation was confirmed. Controlled ovarian stimulation was then started on day 3 using Human Menopausal Gonadotropin (Menogon; Ferring). The dose of gonadotropin was individualized. The patients were monitored with serial ultrasound and serum E2. When at least 3 follicles reached 18 mm, ovulation was triggered using Human Chorionic Gonadotropin 10000 IU (Epifasi 10000 IU; Eipico, Tenth of Ramadan, Egypt) IM and ovum pickup was performed 35 hours later.~All cases received luteal support in the form of progesterone 400 mg twice daily. Embryo transfer was done on day 3 or 5 using Labotect semi-rigid catheter (Labotect GmbH, Kassel area, Germany) under abdominal ultrasound guidance.
Study NCT05566990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIV-GAMMA SN Inj.10%
Description: LIV-GAMMA SN Inj. 10% is administered intravenously at a dose of 1 g/kg daily for 2 consecutive days to patients with primary immune thrombocytopenia.
Study NCT01295515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alpha 2b (PEGINTRON)
Description: pegylated preparation of interferon alpha 2b
Study NCT03114215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: capsules 100mg lactose 3 times per day
Study NCT00659373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Study NCT00659373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Study NCT00659373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Study NCT00659373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Study NCT01735214 — intervention group
Intervention type: DRUG
Intervention: Prostaglandin Analogue -Containing IOP-Lowering Therapy
Description: Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
Study NCT01607320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Thirty PCOS patients treated with 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7 following an initial provera withdrawal
Study NCT01607320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Thirty PCOS patients treated with 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7 following an initial provera withdrawal
Study NCT01672242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: Graded high flow nasal cannula oxygen at 10, 20 , 30, and 40 liters per minute (LPM) to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
Study NCT01672242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Graded contiuous positive airway pressure at 5, 10 , 15, and 20 cm H2O applied to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
Study NCT03294343 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up
Description: Detailed multi-disciplinary counseling, decision-making analysis and long-term follow-up are provided for carriers with any mutation genes but refusal to any risk-reducing gynecologic surgeries
Study NCT03498911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mucogingival surgery
Description: The gingiva around the mucosal recession at implant site will be coronally positioned by releasing the underlying mucosa
Study NCT03498911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mucogingival surgery
Description: The gingiva around the mucosal recession at implant site will be coronally positioned by releasing the underlying mucosa
Study NCT03145857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68]Ga-HA-DOTATATE
Description: All participants will be injected with \[68\]Ga-HA-DOTATATE approximately 60 minutes before PET/CT or PET/MRI scan.
Study NCT04030806 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mirror therapy intervention and control intervention
Description: The exercise protocol will be composed of bimanual activities, performed by both the hands of the patient (paretic and healthy). The same protocol will be applied for both groups (intervention group and control group).~Initially, the desensitization of the limbs will be accomplished by brushing the skin with objects of different textures (sponge, brush, cloths). Afterwards, isolated exercises of fingers (flexion-extension, opposition), wrists (flexo-extension), forearms (prono-supination) and elbows (flexo-extension) and functional exercises such as cleaning a table with a cloth, tightening sponges, roll balls. Each exercise will be performed slowly and repeated for 15 times, totaling three series of each exercise. The protocol used will be based on the proposal of Rothgangel and Braun (2013). The intervention will be carried out by the author of the project and by students of scientific initiation.
Study NCT04030806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy intervention and control intervention
Description: The exercise protocol will be composed of bimanual activities, performed by both the hands of the patient (paretic and healthy). The same protocol will be applied for both groups (intervention group and control group).~Initially, the desensitization of the limbs will be accomplished by brushing the skin with objects of different textures (sponge, brush, cloths). Afterwards, isolated exercises of fingers (flexion-extension, opposition), wrists (flexo-extension), forearms (prono-supination) and elbows (flexo-extension) and functional exercises such as cleaning a table with a cloth, tightening sponges, roll balls. Each exercise will be performed slowly and repeated for 15 times, totaling three series of each exercise. The protocol used will be based on the proposal of Rothgangel and Braun (2013). The intervention will be carried out by the author of the project and by students of scientific initiation.
Study NCT03031873 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI perfusion imaging
Description: Evaluate the evolution of progressive obliteration of the AVM nidus
Study NCT03021733 — intervention group
Intervention type: PROCEDURE
Intervention: Operative management
Description: Rotator cuff surgery
Study NCT01404689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
Study NCT01404689 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: normal saline
Description: 0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
Study NCT04312958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study NCT03527927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Any LABA/LAMA
Description: Following consent, patients will be taken off their current ICS/LABA/LAMA combination inhalers and shown 4 single inhaler LABA/LAMA devices and asked to choose a preferred device to use, provided they can demonstrate effective use.
Study NCT01520727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
Study NCT01520727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single-dose
Study NCT00417911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles
Study NCT00417911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bortezomib
Description: Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles
Study NCT00515021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone (Morning)
Description: Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.~100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks.
Study NCT00515021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone (Night-time)
Description: Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg
Study NCT04662957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic mixture of four Bifidobacterium, five Lactobacillus and one Streptococcus species or placebo
Description: Oral supplementation with multi-strain probiotic preparation
Study NCT04662957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin as placebo
Study NCT03525912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: continuous infusion of low dose ketamine for postoperative pain
Study NCT03154918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIDE
Description: The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8; Peg-ASP 2500 U/m 2 days 4; ifosfamide 1000 mg/m 2 days 1 - 3; dexamethasone 20 mg days 1 - 4; etoposide 100 mg/m 2 days 1 - 3.
Study NCT03798366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: Film-coated tablets of GLPG1690 for oral use.
Study NCT03798366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablets of GLPG1690 matching placebo for oral use.
Study NCT00999882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8055
Description: Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
Study NCT03438773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Envarsus
Description: Patients randomized into the Envarsus group will be prescribed Envarsus, mycophenolate and prednisone once daily.
Study NCT03438773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Patients randomized to the Tacrolimus group will be prescribed Tacrolimus twice-daily with standard of care immunosuppression, anti-proliferative and prednisone once-daily.
Study NCT04134689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DOT Selfie Intervention
Description: This comprises a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders
Study NCT04134689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person DOT
Description: Directly observed TB treatment by a health-worker either in a patient's home or at an agreed upon location within the community.
Study NCT02403089 — intervention group
Intervention type: OTHER
Intervention: Tubes fund recovery blood count
Description: Tubes fund recovery of blood counts among newborns
Study NCT02403089 — intervention group
Intervention type: OTHER
Intervention: the rest of the blood test and stool sample
Description: blood samples on the recovery kinetics after transplant. The rest of the blood test and stool sample done as part of a routine examination.
Study NCT02871024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toraymyxin
Description: Toraymyxin is an extracorporeal hemoperfusion device designed to reduce blood endotoxin levels in sepsis
Study NCT01738568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity aerobic training
Description: High intensity aerobic interval training will be performed 12-weeks. Exercise training will last 1 hour per day, 5 days per week and include high intensity interval cycling at \~70-95% maximum workload for 4 minutes followed by 3 minutes of rest.
Study NCT01738568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary Control
Description: Sedentary control participants will not perform any regular exercise for 12-weeks.
Study NCT00760994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiential acceptance
Description: The experiential acceptance coping condition will focus on changing one's relationship to one's internal events by learning to remain in contact with negative and positive thoughts and feelings and cravings as they are, without defense or judgment or attempting to cling to them (Eifert \& Forsyth, 2005; Hayes, Strosahl, \& Wilson, 1999; Kadden et al., 1992; Levitt, Brown, Orsillo, \& Barlow, 2004).
Study NCT00760994 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive restructuring
Description: The cognitive restructuring coping condition will focus on how to change the content and frequency of internal events by changing one's thinking patterns (Kadden et al., 1992).
Study NCT00760994 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No-intervention control: Nutrition information
Description: The no-intervention condition will be taught the plate method, a nutritional servings guideline, which will have no content related to AUD or PTSD, in order to control for time and contact with a research assistant.
Study NCT06234891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nsaid
Description: Medical treatment
Study NCT06234891 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phsiotheraphy
Description: Nsaid and phsiotheraphy (hotpack-ultrasound therapy- tens)
Study NCT00455780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Phase
Description: Weight loss using CBT and meal replacements
Study NCT02371473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide-placebo
Description: The patients in this arm are given Acetazolamide mg for six days and after 2 weeks washout they are given placebo for six days.
Study NCT02371473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-acetazolamide
Description: The patients in this arm are given placebo for six days and after 2 weeks washout they are given Acetazolamide for six days.
Study NCT04005352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Description: Intra-vitreal injection
Study NCT00607607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC-1
Description: capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles
Study NCT04005352 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2 mg
Description: Intra-vitreal injection